Additive Manufacturing / 3D Printing Software & Services
Strategic Profile
Materialise maintains competitive advantage through its largest group of 3D printing software developers combined with one of the world's largest 3D printing manufacturing facilities. The company is executing a focused strategy where the high-margin Medical segment leads growth, Software stabilizes, and Manufacturing undergoes restructuring toward aerospace and defense.
Cyborg Score Rationale
Materialise demonstrates strong fundamentals with accelerating Medical segment performance (15.4% growth, 32% margins), improving profitability (Q4 2025 net profit doubled), and positive 2026 guidance. However, Manufacturing headwinds and modest stock valuation relative to growth potential temper the outlook.
Top Insights
Medical segment executing at scale: 15.4% growth in 2025 with 32% adjusted EBITDA margins, demonstrating pricing power and expanding adoption in personalized healthcare
Euronext dual-listing (Nov 2025) and €30M share buyback program signal confidence in undervaluation and commitment to shareholder returns
Manufacturing segment restructuring ongoing but strategic: continued exposure to automotive/aerospace headwinds, but potential rebound from aerospace/defense expansion
Strong cash position (€134M cash, €71M net cash) supports growth initiatives and shareholder programs despite near-term manufacturing uncertainty
Named Competitors
Professional 3D Printing Systems — Diversified 3D printing hardware and services provider
Additive Manufacturing Software & Services — 3D printing systems and materials for industrial production
Medical Image Analysis Software — Surgical planning and 3D visualization tools for healthcare
Recent Developments
(February 2026) Q4 2025 results showed 6.8% quarterly revenue growth and net profit doubling; full-year revenue flat but profitability improved
(February 2026) Active share buyback execution at €4.76 average price as part of €30M program announced October 2025
(November 2025) Successful Euronext listing, expanding shareholder base and liquidity beyond NASDAQ
(February 2026) Issued 2026 guidance: €273-283M revenue and €10-12M adjusted EBIT, driven by continued Medical growth
Open the full interactive Materialise NV report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.